Antagonism of bradykinin b2 receptor prevents inflammatory responses in human endothelial cells by quenching the nf-kb pathway activation

HIGHLIGHTS

• who: Erika Terzuoli and collaborators from the Department of Life Sciences, University of Siena, Siena, Italyu0327, Pharmacology Department, Menarini Ricerche SpA, Florence, Italy have published the paper: Antagonism of Bradykinin B2 Receptor Prevents Inflammatory Responses in Human Endothelial Cells by Quenching the NF-kB Pathway Activation, in the Journal: PLOS ONE | www.plosone.org of November/14,/2013
• what: This study aimed to demonstrate that the B2R antagonist, fasitibant, inhibits the BK pro-angiogenic effects, both in in_vitro and in_vivo studies. The authors provide evidence that, in endothelial cells and in circulating proangiogenic cells (PACs . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.